Khaled Maman

844 total citations
14 papers, 633 citations indexed

About

Khaled Maman is a scholar working on Urology, Epidemiology and Rheumatology. According to data from OpenAlex, Khaled Maman has authored 14 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Urology, 7 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Khaled Maman's work include Urinary Tract Infections Management (7 papers), Pelvic floor disorders treatments (7 papers) and Urinary Bladder and Prostate Research (7 papers). Khaled Maman is often cited by papers focused on Urinary Tract Infections Management (7 papers), Pelvic floor disorders treatments (7 papers) and Urinary Bladder and Prostate Research (7 papers). Khaled Maman collaborates with scholars based in France, United Kingdom and Netherlands. Khaled Maman's co-authors include Jameel Nazir, Zalmaï Hakimi, Samuel Aballéa, Emad Siddiqui, Isaac Odeyemi, Con Kelleher, Vanessa Rémy, York Zöllner, Gérard Duru and Richard M. Zur and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Urology and Health and Quality of Life Outcomes.

In The Last Decade

Khaled Maman

14 papers receiving 609 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Khaled Maman France	10	388	313	305	71	67	14	633
Wendy L. Wright United States	13	28 0.1×	27 0.1×	58 0.2×	10 0.1×	67 1.0×	45	525
Barbara A. Majeroni United States	10	8 0.0×	48 0.2×	52 0.2×	4 0.1×	52 0.8×	12	380
Søren Hagstrøm Denmark	13	43 0.1×	51 0.2×	107 0.4×	2 0.0×	44 0.7×	33	412
Parsa Yousefichaijan Iran	10	88 0.2×	18 0.1×	81 0.3×	1 0.0×	20 0.3×	79	319
Pere Sala Spain	10	22 0.1×	7 0.0×	99 0.3×	7 0.1×	62 0.9×	31	334
Yu Liang Lim Singapore	11	13 0.0×	28 0.1×	30 0.1×	22 0.3×	64 1.0×	36	446
Emily Shortridge United States	10	39 0.1×	19 0.1×	61 0.2×	9 0.1×	18 0.3×	20	370
Xinyi Xu China	12	25 0.1×	22 0.1×	86 0.3×	5 0.1×	16 0.2×	29	329
Lolkje T.W. de Jong van den Berg Netherlands	10	10 0.0×	33 0.1×	60 0.2×	14 0.2×	27 0.4×	12	365
Emer Heatley Australia	6	5 0.0×	51 0.2×	242 0.8×	3 0.0×	68 1.0×	6	670

Countries citing papers authored by Khaled Maman

Since Specialization

Citations

This map shows the geographic impact of Khaled Maman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khaled Maman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khaled Maman more than expected).

Fields of papers citing papers by Khaled Maman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khaled Maman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khaled Maman. The network helps show where Khaled Maman may publish in the future.

Co-authorship network of co-authors of Khaled Maman

This figure shows the co-authorship network connecting the top 25 collaborators of Khaled Maman. A scholar is included among the top collaborators of Khaled Maman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khaled Maman. Khaled Maman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Kelleher, Con, Zalmaï Hakimi, Richard M. Zur, et al.. (2018). Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology. 74(3). 324–333. 154 indexed citations

Hakimi, Zalmaï, Con Kelleher, Samuel Aballéa, et al.. (2018). Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. SHILAP Revista de lepidopterología. 6(1). 1438721–1438721. 6 indexed citations

Nazir, Jameel, Con Kelleher, Samuel Aballéa, et al.. (2017). Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis. Neurourology and Urodynamics. 37(3). 986–996. 9 indexed citations

Odeyemi, Isaac, et al.. (2016). Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. Journal of Market Access & Health Policy. 4(1). 31660–31660. 7 indexed citations

Maman, Khaled, et al.. (2015). The value of childhood combination vaccines: From beliefs to evidence. Human Vaccines & Immunotherapeutics. 11(9). 2132–2141. 112 indexed citations

Nazir, Jameel, et al.. (2015). Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. Value in Health. 18(6). 783–790. 24 indexed citations

Aballéa, Samuel, Khaled Maman, Jameel Nazir, et al.. (2014). Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clinical Drug Investigation. 35(2). 83–93. 21 indexed citations

Maman, Khaled, Samuel Aballéa, Jameel Nazir, et al.. (2013). Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. European Urology. 65(4). 755–765. 195 indexed citations

Aballéa, Samuel, et al.. (2013). Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health and Quality of Life Outcomes. 11(1). 200–200. 23 indexed citations

10.

Severens, Johan L., et al.. (2011). Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands. Neuropsychiatric Disease and Treatment. 7. 313–313. 8 indexed citations

11.

Kunz, Dieter, et al.. (2011). Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opinion on Pharmacotherapy. 13(1). 9–16. 24 indexed citations

12.

Nordström, G., Nicolas Despiégel, Florence Marteau, Natalya Danchenko, & Khaled Maman. (2010). Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. Journal of Medical Economics. 13(3). 516–526. 10 indexed citations

13.

François, C., Nicolas Despiégel, Khaled Maman, Delphine Saragoussi, & Pascal Auquier. (2010). Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis. Journal of Medical Economics. 13(1). 99–109. 18 indexed citations

14.

Ereshefsky, Larry, Delphine Saragoussi, Nicolas Despiégel, et al.. (2010). The 6-month persistence on SSRIs and associated economic burden. Journal of Medical Economics. 13(3). 527–536. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact